Long-term survivals of stage IIb XXXX : a 20-year experience in a single institution.

@entity1 @entity7279 @entity5 @entity421 @entity1349
BACKGROUND: The purpose of this study is to evaluate the disease-free survival (DFS) and @entity1349 ( @entity1349 ) of @entity1 with @entity5 at a single institution for 20 years and to compare the results according to the chemotherapy protocols. METHODS: From Jan 1988 to Nov 2008, 167 @entity1 with @entity421 were treated at our hospital and among them, 117 @entity1 (67 males and 50 females) with @entity5 were evaluable. Their mean age was 22.6 years (range, 8 months to 71 years). Seventy-eight cases underwent the modified T10 (M-T10) protocol (group 1), 23 cases underwent the T20 protocol (group 2) and 16 cases underwent the @entity7279 protocol (group 3). The DFS and @entity1349 were calculated and compared according to the chemotherapy protocols. RESULTS: At a mean follow-up of 78.9 months, 63 @entity1 were continuously disease-free (63/117), 6 @entity1 were alive after having metastatic lesions, 7 @entity1 died of other cause and 41 @entity1 died of their disease. The 5- and 10-year @entity1349 rates were 60.2% and 44.8%, respectively and the 5- and 10-year DFS rates were 53.5% and 41.4%, respectively. There was no significant difference of the @entity1349 and DFS between the chemotherapy protocols (p = 0.692, p = 0.113). CONCLUSIONS: At present, we achieved success rates close to the internationally accepted DFS and @entity1349 . We were able to achieve the higher survival rates using the M-T10 protocol over the 20 years. However, there was no significant difference of results between the chemotherapy protocols. We think the M-T10 protocol will achieve more favorable results in the near future.
